Albert Lowe
Stock Analyst at Craig-Hallum
(4.16)
# 1,570
Out of 5,004 analysts
143
Total ratings
46.9%
Success rate
12%
Average return
Main Sectors:
Stocks Rated by Albert Lowe
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CMPX Compass Therapeutics | Reiterated: Buy | $8 | $1.13 | +607.96% | 7 | Sep 23, 2026 | |
| SPRB Spruce Biosciences | Reiterated: Buy | n/a | $48.81 | - | 3 | Sep 17, 2026 | |
| CRDF Cardiff Oncology | Reiterated: Hold | n/a | $1.24 | - | 14 | Sep 15, 2026 | |
| QNCX Quince Therapeutics | Initiated Coverage: Buy | $68 | $31.00 | +119.35% | 1 | Aug 20, 2026 | |
| LCTX Lineage Cell Therapeutics | Reiterated: Buy | n/a | $1.03 | - | 8 | Jul 14, 2026 | |
| IRD Opus Genetics | Reiterated: Buy | n/a | $4.76 | - | 11 | Jul 6, 2026 | |
| PVLA Palvella Therapeutics | Reiterated: Buy | $205 | $138.16 | +48.38% | 6 | Jun 22, 2026 | |
| SABS SAB Biotherapeutics | Reiterated: Buy | $6 | $3.29 | +82.37% | 10 | Jun 16, 2026 | |
| NGNE Neurogene | Reiterated: Buy | $65 | $28.31 | +129.60% | 7 | May 15, 2026 | |
| ACTU Actuate Therapeutics | Reiterated: Buy | $25 → $12 | $0.68 | +1,664.71% | 9 | May 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $19.80 | $11.31 | +75.09% | 12 | May 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $4.22 | - | 1 | Apr 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $1.67 | - | 16 | Mar 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $2 → $4 | $3.90 | +2.56% | 15 | Feb 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $10 | $1.90 | +426.32% | 7 | Feb 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $2.65 | - | 6 | Jan 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $13.86 | - | 1 | Jan 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $4 | $1.33 | +200.75% | 7 | Nov 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $7.30 | n/a | 1 | Jun 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $14 | $295.83 | n/a | 1 | Jun 4, 2024 |
Compass Therapeutics
Sep 23, 2026
Reiterated: Buy
Price Target: $8
Current: $1.13
Upside: +607.96%
Spruce Biosciences
Sep 17, 2026
Reiterated: Buy
Price Target: n/a
Current: $48.81
Upside: -
Cardiff Oncology
Sep 15, 2026
Reiterated: Hold
Price Target: n/a
Current: $1.24
Upside: -
Quince Therapeutics
Aug 20, 2026
Initiated Coverage: Buy
Price Target: $68
Current: $31.00
Upside: +119.35%
Lineage Cell Therapeutics
Jul 14, 2026
Reiterated: Buy
Price Target: n/a
Current: $1.03
Upside: -
Opus Genetics
Jul 6, 2026
Reiterated: Buy
Price Target: n/a
Current: $4.76
Upside: -
Palvella Therapeutics
Jun 22, 2026
Reiterated: Buy
Price Target: $205
Current: $138.16
Upside: +48.38%
SAB Biotherapeutics
Jun 16, 2026
Reiterated: Buy
Price Target: $6
Current: $3.29
Upside: +82.37%
Neurogene
May 15, 2026
Reiterated: Buy
Price Target: $65
Current: $28.31
Upside: +129.60%
Actuate Therapeutics
May 12, 2026
Reiterated: Buy
Price Target: $25 → $12
Current: $0.68
Upside: +1,664.71%
May 5, 2026
Reiterated: Buy
Price Target: $19.80
Current: $11.31
Upside: +75.09%
Apr 2, 2026
Reiterated: Buy
Price Target: n/a
Current: $4.22
Upside: -
Mar 11, 2026
Reiterated: Hold
Price Target: n/a
Current: $1.67
Upside: -
Feb 17, 2026
Reiterated: Hold
Price Target: $2 → $4
Current: $3.90
Upside: +2.56%
Feb 12, 2026
Reiterated: Buy
Price Target: $10
Current: $1.90
Upside: +426.32%
Jan 23, 2026
Reiterated: Buy
Price Target: n/a
Current: $2.65
Upside: -
Jan 12, 2026
Reiterated: Buy
Price Target: n/a
Current: $13.86
Upside: -
Nov 13, 2025
Reiterated: Buy
Price Target: $4
Current: $1.33
Upside: +200.75%
Jun 6, 2024
Reiterated: Buy
Price Target: n/a
Current: $7.30
Upside: n/a
Jun 4, 2024
Initiated Coverage: Buy
Price Target: $14
Current: $295.83
Upside: n/a